Photo taken from Brian Rini/X
Jun 2, 2025, 08:00
Brian Rini: ASCO 2025 HIF inhibitor combination results
Brian Rini, , Chief of Clinical Trials at Vanderbilt University, shared on X:
“ASCO 2025 HIF inhibitor combination results. Shown below is single agent Cabozantinib and Belzutifan for reference, and published HIF-based combo data.
ORR marginally higher
PFS longer but endpoint not reliable in a single-arm trial
Phase 3 trials are planned. Beating TKI may be challenging.”
Tres Uramigas shared a post by Brian Rini on X, adding:
“Phase 1 of casdatifan (HIF2a) + cabozantinib (VEGF TKI) in ccRCC (n=27, short follow-up)
Most patients had no prior VEGF treatment
Well tolerated; anemia and fatigue were the main adverse events
Response rate 41% → PEAK1: cabo/casdatifan vs cabo in pretreated metastatic ccRCC.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 3, 2025, 16:39